CL2023001757A1 - Anticuerpos contra la integrina alfa 11 beta 1 - Google Patents

Anticuerpos contra la integrina alfa 11 beta 1

Info

Publication number
CL2023001757A1
CL2023001757A1 CL2023001757A CL2023001757A CL2023001757A1 CL 2023001757 A1 CL2023001757 A1 CL 2023001757A1 CL 2023001757 A CL2023001757 A CL 2023001757A CL 2023001757 A CL2023001757 A CL 2023001757A CL 2023001757 A1 CL2023001757 A1 CL 2023001757A1
Authority
CL
Chile
Prior art keywords
beta
integrin
antibodies against
against alpha
antibodies
Prior art date
Application number
CL2023001757A
Other languages
English (en)
Spanish (es)
Inventor
Elma Kurtagic
Iii James W Meador
Christopher Beneduce
Original Assignee
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals Inc filed Critical Momenta Pharmaceuticals Inc
Publication of CL2023001757A1 publication Critical patent/CL2023001757A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CL2023001757A 2020-12-18 2023-06-15 Anticuerpos contra la integrina alfa 11 beta 1 CL2023001757A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063127849P 2020-12-18 2020-12-18
US202163213973P 2021-06-23 2021-06-23

Publications (1)

Publication Number Publication Date
CL2023001757A1 true CL2023001757A1 (es) 2024-01-05

Family

ID=79021748

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023001757A CL2023001757A1 (es) 2020-12-18 2023-06-15 Anticuerpos contra la integrina alfa 11 beta 1

Country Status (13)

Country Link
US (1) US20240317865A1 (cg-RX-API-DMAC7.html)
EP (1) EP4263605A2 (cg-RX-API-DMAC7.html)
JP (1) JP2024505790A (cg-RX-API-DMAC7.html)
KR (1) KR20230121831A (cg-RX-API-DMAC7.html)
AU (1) AU2021400221A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023011777A2 (cg-RX-API-DMAC7.html)
CA (1) CA3205574A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023001757A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023008544A2 (cg-RX-API-DMAC7.html)
IL (1) IL303741A (cg-RX-API-DMAC7.html)
MX (1) MX2023007302A (cg-RX-API-DMAC7.html)
TW (1) TW202241946A (cg-RX-API-DMAC7.html)
WO (1) WO2022130318A2 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12022551471A1 (en) 2019-12-20 2023-04-24 Momenta Pharmaceuticals Inc Antibodies against integrin alpha 11 beta 1

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3681787D1 (de) 1985-07-05 1991-11-07 Whitehead Biomedical Inst Expression von fremdem genetischem material in epithelzellen.
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
HK1008049A1 (en) 1987-09-11 1999-04-30 Whitehead Institute For Biomedical Research Transduced fibroblasts and use therefor
ATE110108T1 (de) 1987-12-11 1994-09-15 Whitehead Biomedical Inst Genetische modifizierung von endothelialen zellen.
DE68927996T2 (de) 1988-02-05 1997-12-04 Hughes Howard Med Inst Modifizierte hepatozyten und deren anwendung
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
DE69123981T3 (de) 1990-10-31 2006-06-14 Cell Genesys Inc Nützliche retrovirale vektoren für die gentherapie
SE9201984D0 (sv) 1992-06-29 1992-06-29 Pharmacia Biosensor Ab Improvement in optical assays
US5308341A (en) 1993-09-28 1994-05-03 Becton, Dickinson And Company Method of testing the dose accuracy of a medication delivery device
US6146361A (en) 1996-09-26 2000-11-14 Becton Dickinson And Company Medication delivery pen having a 31 gauge needle
US6302855B1 (en) 1998-05-20 2001-10-16 Novo Nordisk A/S Medical apparatus for use by a patient for medical self treatment of diabetes
US6192891B1 (en) 1999-04-26 2001-02-27 Becton Dickinson And Company Integrated system including medication delivery pen, blood monitoring device, and lancer
US6277099B1 (en) 1999-08-06 2001-08-21 Becton, Dickinson And Company Medication delivery pen
JP4383168B2 (ja) 2001-09-12 2009-12-16 ベクトン・ディキンソン・アンド・カンパニー マイクロ針投与デバイスおよび薬物投与デバイス
FR2849436B1 (fr) 2002-12-27 2007-01-05 Patrick Frayssinet Particules et ceramiques de phosphates de calcium pour transfection in vivo et in vitro
EP3524625A1 (en) * 2018-02-08 2019-08-14 Bergen Teknologioverforing AS Antibody against alpha-11 integrin and its use
US20230065153A1 (en) * 2018-03-01 2023-03-02 Hiroshima University Anti-integrin alpha-11 monoclonal antibody and use thereof
PH12022551471A1 (en) * 2019-12-20 2023-04-24 Momenta Pharmaceuticals Inc Antibodies against integrin alpha 11 beta 1

Also Published As

Publication number Publication date
KR20230121831A (ko) 2023-08-21
AU2021400221A1 (en) 2023-07-13
CA3205574A1 (en) 2022-06-23
US20240317865A1 (en) 2024-09-26
MX2023007302A (es) 2023-09-04
TW202241946A (zh) 2022-11-01
IL303741A (en) 2023-08-01
AU2021400221A9 (en) 2025-03-13
WO2022130318A2 (en) 2022-06-23
EP4263605A2 (en) 2023-10-25
BR112023011777A2 (pt) 2023-10-03
JP2024505790A (ja) 2024-02-08
WO2022130318A3 (en) 2022-08-04
CO2023008544A2 (es) 2023-07-10

Similar Documents

Publication Publication Date Title
CL2020001637A1 (es) Anticuerpos para lilrb2
CL2021001506A1 (es) Anticuerpos que se unen a cd3
CL2022003638A1 (es) Anticuerpos que se unen a cd3
CL2021001366A1 (es) Anticuerpos humanizados contra c-kit
CO2021002954A2 (es) Anticuerpos anti-αvβ8 y composiciones y usos de los mismos
UY38391A (es) Anticuerpos anti-hla-g, composiciones que comprenden anticuerpos anti-hla-g y métodos de uso de anti hla-g
CL2022001667A1 (es) Anticuerpos que se unen a hla-a2 mage-a4
CL2022001673A1 (es) Anticuerpos contra la integrina alfa 11 beta 1.
CO2023015915A2 (es) Anticuerpos anti-ccr8
MX2018015853A (es) Anticuerpos multiespecificos frente a los grupos de diferenciacion 40 y 137 (cd40 y cd137).
CL2017002752A1 (es) Anticuerpos heterodiméricos que unen anticuerpos cd3 y tumorales
AR121370A1 (es) Anticuerpos anti-cd19 humano
UY37494A (es) COMPOSICIONES DE ARNi DE SERPINA1 Y SUS MÉTODOS DE USO
MX2016001236A (es) Anticuerpos anti-fgfr2iiib afucosilados.
CL2020002680A1 (es) Anticuerpos para radionúclidos quelados
CU20160042A7 (es) Anticuerpos conjugados contra antígeno linfocitario 75 para el tratamiento del cáncer
MX2021016098A (es) Moleculas de anticuerpos humanizados contra cd138 y usos de las mismas.
CO2020012593A2 (es) Derivados de oxadiazolina
CO2019011458A2 (es) Anticuerpo monoclonal para pd-l1
MX2019015868A (es) Nueva psicosa-6-fosfato fosfatasa, composición para producir psicosa que incluye dicha enzima, método para producir psicosa usando dicha enzima.
BR112016028252A2 (pt) cambota para suporte e consolidação de uma escavação e método para instalação de uma estrutura para suporte e consolidação de uma escavação
CL2021001511A1 (es) Novedosa psicosa-6-fosfato fosfatasa, composición para la producción de psicosa que comprende la misma y procedimiento para la producción de psicosa mediante el uso de la misma
MX2016007272A (es) Fibra modificada y metodo para producir la misma.
BR112018008045A2 (pt) micro-organismo recombinante que produz l-treonina e um método para produzir l-treonina com o uso do mesmo
CO2024001251A2 (es) Anticuerpos contra el receptor alfa de la interleucina-4 humana